US-based AbbVie (NYSE: ABBV) announced on Friday that it has received approval from the United States Food and Drug Administration (FDA) for its DALVANCE (dalbavancin) to treat acute bacterial skin and skin structure infections (ABSSSI) in paediatric patients from birth.
The product is the first single-dose option administered as a 30-minute intravenous (IV) infusion to treat ABSSSI caused by designated susceptible Gram-positive bacteria in paediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus.
DALVANCE received approval based on results from a multicentre, open-label, actively controlled clinical trial in paediatric patients from birth to less than 18 years of age with ABSSSI and three pharmacokinetic studies. The approved recommended dosage regimen for the product in paediatric patients with a creatinine clearance of 30 mL/min/1.73m2 and above is a single-dose regimen based on the age and weight of the paediatric patient.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML